VivoSeq
Oncology

Cervical Intraepithelial Neoplasia

34

Pipeline Programs↗

9

Active Trials↗

17

Companies Involved↗

Cervical Intraepithelial Neoplasia is a moderately active landscape with 34 programs across 17 companies. The most active players are Nventa Biopharmaceuticals Corporation, Jagotec, Mario Negri Institute for Pharmacological Research. 2 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

11/100

Mech. Concentration

11/100

Completion Rate

68/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Nventa Biopharmaceuticals Corporation

1 program

Phase 1J

Jagotec

1 program

Phase 1Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 1E

Erimos Pharmaceuticals

1 program

Phase 2A

Antiva Biosciences

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

24 of 32 classified programs — the dominant modality here.

25%ALL OTHERSVaccine413%Gene therapy26%Monoclonal antibody13%Radiopharmaceutical13%

Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 100% of 43 pipeline programs.

Analysis

Trial Status

42

clinical trials

Completed19 · 45%
Unknown status5 · 12%
Terminated5 · 12%
Withdrawn4 · 10%
Recruiting4 · 10%
Not yet recruiting4 · 10%
Other1 · 2%

Clinical Trials

Trial Activity

42 trials

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT04712851·25 enrolled
Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment
Recruiting·—·N/A·NCT05405270·410 enrolled
Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma
Recruiting·—·Phase 1·NCT06191133·24 enrolled
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
Recruiting·FFrantz Viral Therapeutics, LLC·Phase 2·NCT04098744·78 enrolled
Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9
Not yet recruiting·—·Phase 3·NCT03848039·1,220 enrolled
A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3
Not yet recruiting·RRinuaGene Biotechnology Co., Ltd.·Phase 1/2·NCT06273553·39 enrolled
Visual Inspection With Acetic Acid of The Cervix Versus Colposcopy in Screening and Detection of Cervical Intraepithelial Neoplasia
Not yet recruiting·SSohag University·N/A·NCT07692919·200 enrolled
A Prospective, Open-label, Randomized, Controlled, Non-inferiority Phase II Study Comparing HAL-PDT With Deferred Surgery Versus Immediate Surgery in Subjects With High-grade Squamous Intraepithelial Lesions (HSIL)
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07669363·230 enrolled
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
Enrolling by invitation·National Cancer Institute (NCI)·N/A·NCT04266093·1,000 enrolled
Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia
Completed·GGenexine, Inc.·Phase 2·NCT02139267·72 enrolled
Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
Completed·National Cancer Institute (NCI)·Phase 2·NCT00303823·98 enrolled
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
Completed·National Cancer Institute (NCI)·Phase 2·NCT00054041·84 enrolled
5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa
Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT05362955·12 enrolled
Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00988559·132 enrolled
SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia
Completed·—·Phase 2·NCT00075569·64 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)